Although the role of serum urate in the causal pathway for gout has been well characterized, substantial controversy exists regarding whether elevated serum urate also may be a cause of high blood pressure, hyperglycemia, and chronic kidney disease; whether the association with serum urate observed in observational studies merely is a consequence of these conditions; or whether it is an artifact of uncontrolled confounding factors. Because the association between genes and disease generally is not subject to confounding by environmental factors or reverse causality, causal inferences between exposure and disease can be examined more specifically using Mendelian randomization. In the present investigation, we tested the
Summary: Coronary artery calcium (CAC) provides prognostic information regarding the risk of cardiovascular events. As a result, the presence of advanced CAC has been proposed as a rationale for aggressive risk factor modification. Using the data from the Multiethnic Study of Atherosclerosis, we assessed the ability of the General Cardiovascular Risk Profile (GCRP) to identify individuals with advanced CAC and determined whether identification of advanced CAC is improved by adding 2 different definitions of a positive family history of coronary heart disease. We defined family history as a dichotomous variable (ie, having ≥1 first-degree relative with premature coronary heart disease) or by familial risk stratification (ie, as a weak, moderate, or strong family history based on number of relatives with coronary heart disease, age at onset, and the presence of stroke or diabetes mellitus in the family). We observed that the GCRP worked well to identify individuals with positive CAC scores, and the addition of family history using either definition improved the discriminatory ability of this model. However, correct reclassification of individuals into lower or higher risk categories for a CAC score >300 was only improved with the addition of familial risk stratification to the GCRP variables. Our findings are consistent with the notion that the GCRP is a general model for assessing global cardiovascular disease risk, and we demonstrate that addition of family history to the GCRP (especially comprehensive familial risk assessment based on the number of relatives with coronary heart disease, age at onset, and the presence of stroke or diabetes mellitus in the family) further enhances the prediction of the presence of advanced CAC.
Conclusions:
The GCRP identifies advanced CAC, an emerging indication for aggressive risk factor modification. Incorporation of family history, especially comprehensive familial risk stratification, provides incremental prognostic value. 1
Ancestry as a Determinant of Mean Population C-Reactive Protein Values: Implications for Cardiovascular Risk Prediction
Summary: Circulating C-reactive protein (CRP) concentration has been proposed as a biomarker for cardiovascular risk prediction and as a selection marker for initiating statin treatment. Most observational studies of CRP and cardiovascular disease have been conducted in Europeans, but average CRP concentrations are thought to differ in populations of non-European ancestry. We conducted a systematic review of published studies to precisely quantify circulating CRP levels in populations of diverse ancestry. Average population CRP values were higher in black and Hispanic individuals, and lower in South and East Asian individuals in comparison with Europeans. The differences were not explained by study design or by the type of CRP assay and were preserved after adjustment for age and body mass index. At 60 years of age, we estimated that 39% of East Asians but 65% of Hispanics have CRP values exceeding 2 mg/L, the cut point used to define eligibility for rosuvastatin treatment for primary prevention of cardiovascular disease in men >50 years and women >60 years. Differences in blood CRP concentration in populations of diverse ancestry are sufficiently large to impact statin eligibility based on a single CRP threshold of 2 mg/L and may be only partially influenced by differences in variables related to cardiovascular risk. A single threshold value of CRP for cardiovascular risk prediction could potentially lead to inequalities in statin eligibility that may not accurately reflect the underlying levels of cardiovascular risk, a premise that warrants further study.
Conclusions: Differences in CRP concentration in populations of diverse ancestry are sufficiently large to affect statin eligibility, based on a single CRP threshold of 2 mg/L, and only partially influenced by differences in variables related to cardiovascular risk. A single threshold value of CRP for cardiovascular risk prediction could lead to inequalities in statin eligibility that may not accurately reflect underlying levels of cardiovascular risk. 2
Context-Dependent Associations Between Variation in Risk of Ischemic Heart Disease and Variation in the 5′ Promoter Region of the Apolipoprotein E Gene in Danish Women
Summary: Genomics research promises to provide DNA information that can be used in medical practice to guide selection of interventions to prevent or treat common diseases, such as ischemic heart disease. A first step toward achieving this goal is to identify DNA sequence variants that are predictors of disease, disease risk factors, or both. To this end, we have demonstrated that 2 single nucleotide polymorphisms in the 5′ regulatory region of the apolipoprotein E gene combine to define genotypes that predict dyslipidemia in samples from multiple populations. These genotypes also predicted risk of ischemic heart disease in Danish women. The positive predictive value of combinations of the 2 single nucleotide polymorphism genotypes is, however, only marginally larger than the cumulative incidence (70/1000), suggesting that they would be a poor choice as a screening test. Using a Patient Rule-Induction Method modeling strategy, we identified a subsample of elderly Danish women with hypertriglyceridemia who had a history of smoking, a history of hypertension, or a history of both and who had particular 2 single nucleotide polymorphism 5′ apolipoprotein E genotypes that had a statistically significant association with higher cumulative incidence of ischemic heart disease (172/1000). This statistical observation is consistent with the established biological reality that the effects of genetic variation on diseases having a complex multifactorial pathobiology are context dependent. Our investigation also underscores the possibility that the most relevant question for genetic studies of complex diseases may extend beyond whether the phenotypic effect of a single-site DNA variation replicates across multiple populations to which multisite genotype is the best predictor of complex disease in which subgroup of the population at large.
Conclusions:
Our study validates that 5′ apolipoprotein E genotypes improve the prediction of ischemic heart disease and documents that the improvement is greatest in a subset defined by a particular combination of traditional risk factors in Copenhagen City Heart Study female participants. We discuss the use of these genotypes in medical risk assessment of ischemic heart disease in the population represented by the Copenhagen City Heart Study. 4
Association of a Peripheral Blood Metabolic Profile With Coronary Artery Disease and Risk of Subsequent Cardiovascular Events
Summary: Coronary artery disease (CAD) is the leading cause of death in industrialized countries, and many accepted risk factors for CAD are metabolic. However, we have an incomplete mechanistic understanding of CAD risk, and equally important, there is a need to refine our ability to identify individuals at the highest risk of cardiovascular events. New molecular profiling tools may help improve risk stratification and enhance our understanding of the disease process. Metabolomics is a novel technology used to study the small-molecule metabolites that are by-products of cellular metabolism and that may be particularly useful for the diagnosis of human disease. Therefore, in this study, we performed quantitative metabolomic profiling of 69 metabolites, including acylcarnitine species (by-products of mitochondrial metabolism), amino acids, and conventional metabolites. Profiling was performed in peripheral blood samples from 2 independent CAD case-control data sets of participants enrolled in the Duke CATHGEN biorepository of patients undergoing cardiac catheterization. We observed that 2 metabolomic biosignatures were independently associated with CAD in both case and control data sets, 1 comprising metabolites from the branched-chain amino acid pathway and 1 from the urea cycle pathway. The metabolomic signatures also seemed to add discriminative capability to models with clinical risk factors alone. A third metabolomic biosignature in the blood was able to independently predict who would experience future cardiovascular events (death or myocardial infarction). Hence, these metabolomic signatures may represent useful markers for the presence of CAD, potentially improve risk stratification, and identify novel mechanisms of CAD pathophysiology.
Conclusions: Metabolite profiles are associated with CAD and subsequent cardiovascular events. 5
Genomic Risk Variants at 1p13.3, 1q41, and 3q22.3 Are Associated With Subsequent Cardiovascular Outcomes in Healthy Controls and in Established Coronary Artery Disease
Summary: The genomic risk loci at 1p13.3, 1q41, and 3q22.3 have been strongly associated with the risk of developing coronary heart disease in many large genome-wide association and cohort studies. This study investigated whether these important coronary artery disease risk variants may also contribute to disease progression and poorer outcomes in patients with established cardiovascular disease. Whether these risk loci also increase the risk of subsequently experiencing a cardiovascular event in individuals with no known overt cardiovascular disease at the time of recruitment was assessed. The findings from this study support previous associations between 1p13.3 and myocardial infarction and lipid levels. Extending these findings, we observed in patients with coronary heart disease an association between 1p13.3 and readmission for non-ST-segment elevation myocardial infarction and between 1q41 and the composite end point of death/cardiovascular disease readmission. The coronary artery disease risk locus at 3q22.3 was associated with subsequent survival/admission for cardiovascular disease event in individuals who were free of overt coronary artery disease at the time of study inclusion. These findings provide further evidence for an important role of 1p13.3, 1q41, and 3q22.3 in coronary artery disease. Furthermore, this study suggests that variants at 1p13.3 and 1q41 are independently associated with clinical outcomes in patients with established coronary heart disease and confirms 3q22.3 as a predictor of cardiovascular risk in individuals free of overt heart disease.
Conclusions: These data suggest that coronary artery disease genomic risk variants at 1p13.3 and 1q41 are associated with subsequent clinical outcome in heart patients and confirm rs9818870 at 3q22.3 as a predictor of cardiovascular risk in individuals free of overt heart disease. 6
Physical Activity Modifies the Effect of LPL, LIPC, and CETP Polymorphisms on HDL-C Levels and the Risk of Myocardial Infarction in Women of European Ancestry
Summary: Genome-wide association studies have identified a number of common genetic polymorphisms that are associated with alterations in high-density lipoprotein cholesterol (HDL-C). However, few studies have examined the ways in which common behaviors that also affect HDL-C, such as regular physical activity, might modify the association of these newly discovered polymorphisms with HDL-C levels and cardiovascular risk. In a cohort of >22 000 women, we found that the association of common variations in lipoprotein lipase (LPL), hepatic lipase (LIPC), and cholesteryl ester transfer protein (CETP) with HDL-C are modified by regular physical activity. Although the effects of common variation in LIPC and CETP on HDL-C were larger in active women, the reverse was seen for common variation in LPL. There, the effects were larger among less active women. Among women with a copy of the polymorphism in LPL, regular physical activity was associated with a lower risk of heart attack. By contrast, among women without the polymorphism at LPL, regular physical activity was not associated with the risk of heart attack. The polymorphism in CETP was associated with a reduced risk of heart attack of similar magnitude in both active and inactive women. Although these results will need to be replicated in other cohorts, they raise the possibility that the effects of physical activity on cardiovascular health may vary according to an individual's genotype.
Conclusions:
The effects of common variants in the LPL, LIPC, and CETP genes on HDL-C levels are modified by physical activity. For a common variant in LPL, the impact on myocardial infarction varied by activity level, whereas the effects of a common variant in CETP on myocardial infarction risk did not. 7
Common Variants in CASQ2, GPD1L, and NOS1AP Are Significantly Associated With the Risk of Sudden Death in Patients With Coronary Artery Disease
Summary: Sudden cardiac death (SCD) remains a public health problem of significant magnitude, and the key to prevention is improvement in risk stratification methodology. Recent studies have shown that there is evidence of a genetic component even among patients with coronary disease who have SCD, the most common yet complex form of this condition. We used high-throughput genetic analysis to evaluate the potential role of genes that are known to be causative in more rare, familial forms of SCD, such as the long-QT and Brugada syndromes. The results indicate that common variations in the genes known to be involved in the rare syndromes are also associated with SCD in the more common and complex coronary artery disease manifestation. These findings provide evidence for a unifying genetic link between rare and common forms of SCD and are likely to inform the development of enhanced risk stratification methodologies.
Conclusions: Common variations in or near CASQ2, GPD1L, and NOS1AP are associated with increased risk of SCD in patients with coronary artery disease. These findings provide further evidence for overlap between the genetic architecture of rare and common forms of SCD, and replication in additional populations is warranted. 8
Growth-Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Non-ST-Segment Elevation Acute Coronary Syndrome
Summary: Growth-differentiation factor-15 (GDF-15) is a member of the transforming growth factor-β cytokine superfamily that is induced in the myocardium in response to oxidative stress, inflammation, or tissue injury. Circulating GDF-15 has been shown to be a strong predictor of adverse outcome in patients with chronic heart failure and acute manifestations of ischemic heart disease. In this study, the evidence regarding the prognostic significance of circulating GDF-15 is extended to patients who had been stabilized after an episode of non-ST-segment elevation acute coronary syndrome and who were followed for 5 years. We observed that circulating GDF-15 levels, despite a slight, but significant decrease during the first 6 months after non-ST-segment elevation acute coronary syndrome, were consistently related to cardiovascular risk factors and biochemical markers of hemodynamic stress, renal dysfunction, and inflammation. Moreover, higher blood GDF-15 concentration was independently related to an increased risk of developing adverse outcomes (ie, mortality) and the composite of mortality and recurrent ischemic events. The associations of GDF-15 with risk were remarkably consistent over time. This finding distinguishes GDF-15 from other established biochemical risk indicators, which often exhibit changing relationships to outcome as time passes after an acute ischemic event.
Overall, our data underscore the potential role of GDF-15 as a prognostic biomarker over the entire time course of acute ischemic heart disease from the phase of acute coronary instability to the subsequent phase of clinical stabilization and extending into the chronic stage of coronary artery disease.
Conclusions: GDF-15 is independently related to adverse events in non-ST-segment-elevation acute coronary syndrome both in the acute setting and for ≥6 months after clinical stabilization. Therefore, continued research on GDF-15 should be focused on the usefulness of GDF-15 for support of clinical management in acute and chronic ischemic heart disease. 9
Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease but Not With Stroke Risk in the Heart Protection Study
Summary: Recent genetic studies have demonstrated strong support for a causal role of plasma levels of lipoprotein(a) [Lp(a)] in coronary disease. The current findings from the Heart Protection Study, which are based on >12 000 prevalent disease cases and >3000 incident events, increase our understanding of the relevance of Lp(a) for vascular disease risk. The Heart Protection Study demonstrates comparable strength of associations of an LPA genotype score, previously shown to explain more than half of the genetic variation in Lp(a) levels with coronary disease and peripheral vascular disease but not with stroke. These results indicate that Lp(a) may have effects on atherosclerotic and thrombotic diseases that are only relevant at specific sites. Furthermore, as indicated by the paradoxical results from prospective and randomized evidence for cholesterol and ischemic stroke risk, the lack of evidence of an association of LPA and stroke in the present study does not exclude the possibility that lowering Lp(a) could have beneficial effects on the risk of stroke or stroke subtypes. The results of large-scale randomized trials of agents that reduce plasma levels of Lp(a), such as niacin and cholesteryl ester transfer protein inhibitors, will help to assess the safety and efficacy of lowering Lp(a) levels on a broad range of vascular outcomes.
Conclusions:
The comparable strength of associations of the LPA score with coronary disease and peripheral vascular disease but not with stroke suggest that lipoprotein(a) may have effects on atherothrombotic vascular disease that are only relevant at specific sites. 10
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Associations of Lipoprotein Lipase Gene Polymorphisms With Longitudinal Plasma Lipid Trends in Young Adults: The Coronary Artery Risk Development in Young Adult Study
Summary: Lipoprotein lipase plays a key role in the metabolism of lipoproteins and regulation of triglyceride and high-density lipoprotein cholesterol levels. On the basis of the data from 2045 black and 2116 white young adults, spanning 20 years and 7 examinations, we detected multiple variants in the lipoprotein lipase gene that are associated with interindividual differences in triglycerides and highdensity lipoprotein cholesterol and with longitudinal changes in the 2 lipids during 20 years of life span. Our findings may provide useful information in risk prediction and intervention for lipid disorders and coronary heart disease.
Conclusions: Our data suggest that aging interacts with LPL gene variants to influence the longitudinal lipid variations, and there is population-related heterogeneity in the longitudinal associations. 11
Apolipoprotein Isoform E4 Does Not Increase Coronary Heart Disease Risk in Carriers of Low-Density Lipoprotein Receptor Mutations
Summary: In humans, the E4 allele of the apolipoprotein E gene is associated with increased coronary heart disease risk next to its well-known association with Alzheimer disease risk. We investigated whether the presence of a low-density lipoprotein receptor mutation in patients clinically diagnosed with familial hypercholesterolemia was protective in E4/E4 carriers. In a cohort of 2400 patients clinically diagnosed with familial hypercholesterolemia, we found a lowdensity lipoprotein receptor gene mutation in 1383 patients, whereas in 1013 patients, such mutation was not present. In 92 patients homozygous for APOE4, the presence of a low-density lipoprotein receptor mutation conferred lower coronary heart disease risk (hazard ratio, 0.16; 95% CI, 0.05-0.58; P=0.005). From these results, we can conclude that the low-density lipoprotein receptor function is key to the detrimental effects of apolipoprotein E4 in humans. Further studies are now required to study the consequences of our observation for the prevention of both coronary heart disease and Alzheimer disease.
Conclusions: Low-density lipoprotein receptor function is key to the detrimental effects of apolipoprotein E4 in humans. Kinetic studies in humans are now required to study the consequences of our observation for the prevention of both coronary heart disease and Alzheimer disease. 12
Effect of Genetic Variations in Syntaxin-Binding Protein 5 and Syntaxin 2 on von Willebrand Factor Concentration and Cardiovascular Risk
Summary: It has been well established that elevated von Willebrand factor (VWF) plasma levels are associated with an increased risk of cardiovascular disease. A meta-analysis of genome-wide association studies on VWF identified novel candidate genes, that is, syntaxinbinding protein 5 and syntaxin 2 (STX2). STX2 is a binding substrate for syntaxin-binding protein 5 and is a member of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor family. These proteins drive vesicle exocytosis by fusion of granules and target membranes, which may be involved in the secretion pathway of VWF multimers. We investigated whether VWF antigen levels (VWF:Ag), VWF collagen-binding activity (VWF:CB), and the risk of arterial thrombosis are affected by common genetic variations in these genes. In a case-control study with 463 young white subjects (men ≤45 years of age and women ≤55 years of age), who were included 1 to 3 months after a first event of arterial thrombosis, and 406 control subjects, we showed that common genetic variations in syntaxin-binding protein 5 and STX2 affect both VWF concentration and activity in young individuals with premature arterial thrombosis. We also demonstrated that the minor alleles of genetic polymorphisms in STX2 are associated with a decreased risk of arterial thrombosis. However, this alteration of the risk of arterial thrombosis was not explained by variation in VWF plasma levels. Our findings form a basis for future research on the role of soluble N-ethylmaleimidesensitive factor attachment protein receptors in the secretion pathway of VWF multimers and on their possible importance in the development of arterial thrombosis.
Conclusions: Genetic variability in syntaxin-binding protein 5 and STX2 affects both VWF concentration and activity in young individuals with premature arterial thrombosis. Furthermore, in our study, genetic variability in STX2 is associated with the risk of arterial thrombosis. However, at this point, the underlying mechanism remains unclear. 13
Association of Genetic Risk Variants With Expression of Proximal Genes Identifies Novel Susceptibility Genes for Cardiovascular Disease
Summary: Over recent years, variations in the DNA sequence, socalled single nucleotide polymorphisms (SNPs), have been increasingly acknowledged as genetic modulators of the risk of developing cardiovascular disease. Several large-scale genome-wide association studies have identified hundreds of SNPs associated with cardiovascular disease or important risk factors. It is usually assumed that the gene located closest to the SNP site is the so-called risk gene responsible for the effect of the SNP, but this may not be true. In this investigation, we sought to identify the culprit genes likely to mediate the effect of SNPs associated with cardiovascular disease. By combining gene expression measurements in liver, plaque, and vessel wall with 156 SNPs associated to cardiovascular disease, we demonstrate that the effect of SNPs are tissue-and phenotype-specific. Furthermore, in >20 instances, the culprit gene was not directly deducible from the location of the risk SNP. An important promise of genome-wide association studies is the ability to identify novel pathobiological pathways and new concepts for therapy. To fully understand the role of SNPs in mediating disease and to develop novel treatments, accurate knowledge of the functional consequences of genetic variation is essential. The present study emphasizes the necessity of combining functional studies of genetic markers with association data to realize the full potential of current genomic research.
Conclusions: This study demonstrates several instances of association between risk SNPs and genes immediately adjacent to them. It also demonstrates instances in which the associated gene is not the immediately proximal and obvious candidate gene for disease. This shows the necessity of careful studies of genetic marker data as a first step toward application of genome-wide association study findings in a clinical setting. 14
Association of Known Loci With Lipid Levels Among Children and Prediction of Dyslipidemia in Adults
Summary: Recent genome-wide association studies have identified 95 single nucleotide polymorphisms associated with blood lipid levels in adult populations. We studied these genetic variants both individually and as multilocus genetic risk scores (GRSs) and estimated their association with lipid levels of Finnish children and adolescents in Cardiovascular Risk in Young Finns Study. We observed that the lipid-specific GRSs were associated with lipids over the whole age span of the study (3-45 years). In total, the loci explained ≈2 times more of high-density lipoprotein cholesterol, lowdensity lipoprotein cholesterol, and total cholesterol variation among young children than in adults. The GRSs improved the risk prediction of adult hypertriglyceridemia over childhood lipid measurements, which suggests that GRSs may potentially provide useful additional information in the initial assessment of an individual's risk for heart disease. Identifying children with high genetic risk for coronary heart disease could provide a reasonable classification of individuals who would benefit from systematic follow-up of their cholesterol levels, blood pressure, and other coronary heart disease risk factors. However, further studies with more complete single nucleotide polymorphism panels and life course information are needed to evaluate the clinical utility of these GRSs.
Conclusions: Previously identified lipid loci are associated with lipid levels in children and adolescents and explain up to >2 times of the lipid variation in children compared with adults. The TG-GRS improves the risk discrimination over childhood lipid measurement for adult hypertriglyceridemia. 15
Genetic Regulation of Serum Phytosterol Levels and Risk of Coronary Artery Disease
Summary: Phytosterols interfere with intestinal cholesterol absorption; therefore, supplementation of phytosterols in functional foods (eg, margarines and yogurts) is widely used for their potential to lower serum cholesterol. A certain fraction (usually <5%) of phytosterols is absorbed. Although the human body has very efficient means of eliminating these sterols, supplementation of phytosterols in functional foods has been shown to double their serum levels. Other than that, plasma sterol levels are under tight genetic control, with heritability estimates of ≈80%. We performed a genome-wide association study investigating genetic variability of serum phytosterol levels in the general population. We found that ≈10% of the variability of phytosterol levels was explained by 3 independent genetic variants at the ATP-binding cassette hemitransporter ABCG8 and ABO blood group gene loci. Because there is growing evidence for a potential proatherogenic role of phytosterols, we investigated whether genetic variants affecting phytosterols also modulate coronary artery disease risk. Strikingly, we found that common genetic variants associated with increased serum phytosterol levels increase coronary artery disease risk as well. Our findings might have potential relevance with regard to the use of phytosterols as food supplements.
Conclusions: Common variants in ABCG8 and ABO are strongly associated with serum phytosterol levels and show concordant and previously unknown associations with coronary artery disease. 16
A Common Genetic Variant in the 3′-UTR of Vacuolar H + -ATPase ATP6V0A1 Creates a MicroRNA Motif to Alter Chromogranin A Processing and Hypertension Risk
Summary: In this article, we explored molecular mechanisms of how a polymorphism (T+3246C) in the 3′-untranslated region of the proton translocating ATPase (V-ATPase) subunit ATP6V0A1 influences human cardiovascular traits, including chromogranin A and blood pressure. First, using a luciferase reporter plasmid, we found that the C (variant) allele of T+3246C (rs938671) decreased overall gene expression. The 3′-untranslated region effect was verified by coupled in vitro transcription/translation of the entire/intact human ATP6V0A1 mRNA. Second, by overexpression and knockdown of a specific microRNA, we found that T+3246C disrupted a microRNA recognition motif for hsa-miR-637. Third, because ATP6V0A1 is an important component of the V-ATPase, chromatin granule pH was monitored by fluorescence of a chromogranin A/enhanced green fluorescent protein chimera: the +3246C allele impaired control of vacuolar pH. Fourth, increased pH (caused by the C allele) was then mimicked by the V-ATPase inhibitor bafilomycin A1. After bafilomycin A1, the ratio of chromogranin A precursor to its catestatin fragment was diminished. Bafilomycin A1 also decreased exocytotic secretion from the regulated pathway. The results point to new molecular and mRNA translational strategies for probing autonomic control of the circulation, and ultimately the susceptibility to and pathogenesis of cardiovascular disease states such as hypertension.
Conclusions:
The results suggest a series of events whereby ATP6V0A1 3′-untranslated region variant T+3246C functioned: ATP6V0A1 expression probably was affected through differential microRNA effects, altering vacuolar pH and consequently chromogranin A processing and exocytotic secretion. 17
Plasma Bilirubin and UGT1A1*28 Are Not Protective Factors Against First-Time Myocardial Infarction in a Prospective, Nested Case-Referent Setting
Summary: Antioxidants have been implicated to have a protective effect, and bilirubin is an endogenous antioxidant in humans. Homozygosity for UGT1A1*28, an insertion of a TA segment in the promoter region of the UGT1A1 gene, is the main genetic determinant of circulating bilirubin levels, including the benign rise seen in the Gilbert syndrome. We report on an inverse association between circulating bilirubin levels and incidence of a first myocardial infarction in our prospective study including 618 incident cases. This observation is consistent with several previous studies relating bilirubin levels to the risk of developing myocardial infarction and cardiovascular diseases. However, the earlier studies on myocardial infarction have not included determination of the UGT1A1*28 polymorphism. Homozygosity for this polymorphism was not associated with risk in our study. Because there was no risk association between UGT1A1*28 and first-time myocardial infarction, our study raises the possibility that bilirubin may not be an independent risk factor associated with future risk of developing a myocardial infarction in white population samples.
Conclusions:
We found no evidence for a protective effect of the UGT1A1*28 polymorphism against myocardial infarction and consequently neither for bilirubin. The lower bilirubin levels in cases might be caused by decreased production, increased degradation, or increased elimination. 18
Association of Single Nucleotide Polymorphisms From 17 Candidate Genes With Baseline Symptom-Limited Exercise Test Duration and Decrease in Duration Over 20 Years: The Coronary Artery Risk Development in Young Adult Fitness Study
Summary: Cardiorespiratory fitness-related phenotypes have been shown to have a substantial genetic component in numerous epidemiological studies. However, identifying common genetic variants associated with changes in health-related fitness phenotypes over time in large population-based studies has proven difficult because of the lack of appropriate data sets and the feasibility of measuring fitness in a large group of people. We observed in the Coronary Artery Risk Development in Young Adults Fitness Study that carrying several favorable alleles at loci shown to be independently associated with baseline exercise test duration or with change in exercise duration resulted in a ≈2.5-minute longer baseline treadmill time in blacks and a 1-minute lesser decrease in treadmill time over 20 years in whites. Thus, these data provide evidence of both the independent and the conjoint effects of multiple markers from several candidate genes on symptom-limited exercise test duration in young adults and with change in exercise test duration over 20 years. Symptom-limited exercise tests have important clinical relevance for evaluating exercise tolerance because many individuals may not be able to perform a true maximal exercise test to exhaustion. These results are of interest to clinicians because exercise duration in Coronary Artery Risk Development in Young Adults participants was shown to be predictive of the development of cardiovascular disease risk factors, such as diabetes mellitus, hypertension, and metabolic syndrome. Understanding the underlying genetic basis of the ability to benefit from regular exercise can likely facilitate custom-tailored programs and therapies for individuals with less favorable genotypes.
Conclusions:
In multimarker constructs, alleles at genes related to skeletal muscle Na + /K + transport, hypoxia, and mitochondrial metabolism are associated with symptom-limited exercise test duration over time in adults. 19
Clinical and Genetic Correlates of Circulating Angiopoietin-2 and Soluble Tie-2 in the Community
Summary: Experimental studies suggest that endothelial growth factors play an important role in angiogenesis and vascular remodeling. We evaluated the clinical and genetic correlates of circulating angiopoietin-2 (Ang-2) and its soluble receptor/regulator Tie-2 (sTie-2) in a community-based sample. Ang-2 levels were higher and sTie-2 levels were lower in women than in men. Ang-2 was positively related to age, smoking, systolic blood pressure, hypertension treatment, and diabetes mellitus, whereas sTie-2 was positively associated with body mass index, diabetes mellitus, and triglycerides. Circulating Ang-2 and sTie-2 were higher in participants with the metabolic syndrome, with stronger associations of Ang-2 with blood pressure traits and of sTie-2 with obesity-dyslipidemia components. Heritability estimates for Ang-2 and sTie-2 were 27% and 56%, respectively. A region on chromosome 9 was significantly linked to circulating sTie-2 levels (log of the odds score, 8.31). These observations are consistent with the concept that angiogenesis and vascular remodeling are influenced by genetic factors and associated with metabolic risk factors.
Conclusions: Circulating levels of Ang-2 and sTie-2 are heritable traits associated with cardiovascular disease risk factors, including the metabolic syndrome. These observations are consistent with the notion that angiogenesis and vascular remodeling are determined, in part, by genetic influences and associated with metabolic risk factors. 20
Genetic and Clinical Correlates of Early-Outgrowth Colony-Forming Units
Summary: Cells termed endothelial progenitor cells (EPCs) have attracted interest as potential biomarkers and even cellular therapies for cardiovascular disease. This enthusiasm stems from studies suggesting that lower EPC number is associated with increased risk of cardiovascular disease and events and the hypothesis that EPCs, broadly defined, contribute to endothelial repair. However, this literature encompasses several different phenotypic definitions of EPCs and small to medium-sized patient samples. In the present study, we measured a specific EPC phenotype, early-outgrowth colonyforming units (CFUs), in 1799 participants of the Framingham Heart Study. Among individuals without cardiovascular disease, CFUs showed significant inverse associations with the Framingham Risk Score, advanced age, female sex, and triglycerides; positive associations were found with hormone replacement and statin therapy. In a genome-wide association study, polymorphisms were significantly associated with CFUs at the MOSC1 and the SLC22A3-LPAL2-LPA loci; SLC22A3-LPAL2-LPA is a previously replicated susceptibility locus for myocardial infarction. Alleles at the SLC22A3-LPAL2-LPA locus that were associated with decreased CFUs were also highly related to increased risk of myocardial infarction. These data support the hypothesis that decreased CFU number promotes susceptibility to myocardial infarction in a community sample and warrant independent replication and further mechanistic studies.
Conclusions:
In a community-based sample, early-outgrowth CFUs are inversely associated with select cardiovascular risk factors. Furthermore, genetic variants at the SLC22A3-LPAL2-LPA locus are associated with both decreased CFUs and an increased risk of myocardial infarction. These findings are consistent with the hypothesis that decreased circulating angiogenic cell populations promote susceptibility to myocardial infarction. 21
The Coronary Artery Disease-Associated 9p21 Variant and Later Life 20-Year Survival to Cohort Extinction
Summary: The single nucleotide polymorphisms at chromosome 9p21 emerged as the inherited genetic variant with the largest effect that is associated with coronary artery disease (CAD) and myocardial infarction in middle-aged groups. Some have speculated that the effect dwindles in later life. We examined the single nucleotide polymorphism effect on cardiovascular mortality in a population-based cohort aged >70 years with no prior cardiovascular disease diagnoses and followed up for 20 years, by which time ≈95% had died. Those with the 9p21 risk variant were significantly more likely to die with a cardiovascular diagnosis: the hazard ratio was ≈50% higher for the 25% of the population with 2 risk alleles compared with those with 0 risk alleles. We found that this effect was reduced for those aged >80 years. Adding the 9p21 variant to the risk prediction formula in middle age has little impact because conventional risk factors provide efficient prediction. In older groups, several traditional risk factors for CAD lose their predictive capacity, so could the 9p21 variant help? Modeling 9p21 into the Framingham Risk Score for CAD resulted in 6% more of those who died within 10 years being classified to the highest risk group, mainly from the middle-risk band. This improved prediction warrants further evaluation, given the high incidence rates and effectiveness of intervention in later life.
Conclusions:
In 71-to 80-year-old subjects free of CAD diagnoses, 9p21 is associated with excess mortality, mainly attributed to CAD mortality. Adding 9p21 to the FRS may improve the targeting of CAD prevention in older people, but validation in independent samples is needed for confirmation. 22
Improved Prediction of Cardiovascular Disease Based on a Panel of Single Nucleotide Polymorphisms Identified Through Genome-Wide Association Studies
Summary: In the past 3 years, several genome-wide association studies have identified common genetic variants at multiple loci that are significantly associated with coronary artery disease (CAD) risk. The most robust of these is a risk allele at 9p21 that has been shown to modestly but inconsistently improve CAD risk prediction over and above conventional risk factors. However, the extent to which additional recently identified genetic variants of more modest effect size cumulatively improve risk prediction remains controversial.
In the present study, we demonstrate, in 2 large CAD case-control populations, that a collective of 12 previously replicated CADassociated single nucleotide polymorphisms confers significantly greater predictive capabilities than do traditional risk factors or traditional risk factors plus 9p21. We also show that logistic regression performs better than more complicated machine-learning approaches. Large meta-analyses of CAD case-control data sets including >100 000 individuals are underway. Relevant to the goal of personalized medicine, more informative risk prediction models can be expected because additional CAD-associated single nucleotide e44 Circ Cardiovasc Genet October 2012
polymorphisms are identified and more refined phenotypic data become available.
Conclusions: Using the collective of 12 SNPs confers significantly greater predictive capabilities for CAD than 9p21.3, whether traditional risks are or are not considered. More accurate models probably will evolve because additional CAD-associated SNPs are identified. 23
Copy Number Variation in Glutathione S-Transferases M1 and T1 and Ischemic Vascular Disease: Four Studies and Meta-Analyses
Summary: Glutathione S-transferases (GSTs) M1 and T1 detoxify products of oxidative stress and may protect against atherosclerosis and ischemic vascular disease (IVD). We tested the hypothesis that copy number variation (CNV) in GSTM1 and GSTT1 genes, known to be associated with a stepwise decrease in catalytic activity, predicted the risk of IVD. The principal finding of this study is that CNV in GSTM1 and GSTT1 is not associated with risk of ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, ischemic stroke, or any ischemic vascular event. The absence of an association between CNV in GSTM1 or GSTT1 and risk of IVD was consistently observed in 4 large studies, including 2 studies of the general population and 2 case-control studies comprising 6557 IVD cases and 16 502 controls, and in meta-analyses comprising 13 196 IVD cases and 33 228 controls. Furthermore, these associations were not affected by smoking exposure status. Finally, GST genotypes were not associated with markers of inflammation and oxidation or interacted with smoking status to influence concentrations of markers of inflammation in the general population. In contrast, we observed the well-established association between CNV in GSTM1 and risk of bladder cancer.
Conclusions:
In studies including 6557 IVD cases and 16 502 controls and in meta-analyses of 13 196 cases and 33 228 controls, CNV in GSTM1 and GSTT1 genes did not associate with risk of IVD or with markers of inflammation. These observations were independent of smoking exposure. 24
Relative Familial Clustering of Cerebral Versus Coronary Ischemic Events
Summary: Although differences in heritability of cerebrovascular and coronary artery disease may improve risk prediction, future genetic studies, and understanding of disease mechanisms, the relative heritability of acute cerebral and coronary events has rarely been studied. In a prospective, population-based study, the family history of myocardial infarction (MI) and stroke in first-degree relatives was compared between patients presenting with acute coronary syndromes and patients presenting with transient ischemic attacks and stroke. Nine hundred six patients with acute coronary syndromes and 1015 with transient ischemic attacks and stroke were compared. Although parental MI and stroke were common in both patient populations, there was greater clustering of MI than of stroke within families. Patients with acute coronary syndromes were 5× more likely than patients with strokes or transient ischemic attacks to have 2 or more siblings with disease in the same arterial territory, despite similar overall incidence of MI and stroke in our study population. Moreover, the relative heritability of MI was greater than stroke because parental MI predicted sibling MI, whereas parental stroke did not predict sibling stroke. The use of composite measures of family history of vascular disease in risk scores and in screening may not be optimal because the heritability of stroke is much less than that of MI. Genome-wide scanning is unlikely to identify causative gene loci for stroke, given the finding of substantially greater heritability of MI versus stroke and the relatively small number of major loci discovered in relation to MI to date.
Conclusions: Heritability of coronary events was greater than that of cerebral events, such that MI was more likely to cluster in families than was stroke. 25
Genetic Association of the CCR5 Region With Lipid Levels in At-Risk Cardiovascular Patients
Summary: Evidence suggests a role for the chemokine receptor 5 (CCR5) in the development and progression of atherosclerosis; knockout studies have confirmed a critical role for CCR5 in macrophage accumulation and plaque formation, and attenuation of atherogenesis has been demonstrated in low-density lipoprotein receptor null mice treated with CCR5 and chemokine receptor 3 receptor antagonists. Several human genetic studies have demonstrated a protective effect of the CCR5Δ32 deletion with cardiovascular disease; however, other studies have shown no relationship with cardiovascular events. Differences in study design and relatively small sample sizes may contribute to these inconsistencies. In this investigation, we performed a comprehensive evaluation of 27 genetic variants, including CCR5Δ32, across the chemokine receptor 2-CCR5-chemokine receptor-like protein 2 (CCRL2) gene region in 5748 white subjects participating in the Treating to New Targets (atorvastatin) cardiovascular events trial. Results demonstrated an association between the CCR5Δ32 deletion and higher plasma high-density lipoprotein cholesterol and lower plasma triglyceride levels as well as an association between 3 CCRL2 single nucleotide polymorphisms and higher plasma high-density lipoprotein cholesterol. These associations were replicated in a second population-based study (Incremental Decrease in Endpoints through Aggressive Lipid Lowering) in which 6635 white participants were genotyped. Although the findings do not imply a causal effect for the associated single nucleotide polymorphisms, it is possible that the functional genetic variant underlying the observed associations may reside within CCR5 or CCRL2 genes. Overall, our data support the hypothesis that functional changes in the CCR5 region might positively affect cardiovascular disease in some part by influencing circulating lipid levels. Identification of the functional variant underlying these beneficial associations potentially may lead to the development of a novel and adjunctive approach for the treatment of dyslipidemia and cardiovascular disease, respectively.
Conclusions:
Our study provides evidence that a locus within the region of the genome encompassing the CCR5-CCRL2 region is associated with lipid levels and suggests that chemokine activity influences lipid levels in populations with preexisting cardiovascular disease. 26
A Genome-Wide Association Study Identifies LIPA as a Susceptibility Gene for Coronary Artery Disease
Summary: In relation to polygenic coronary artery disease (CAD), recent genome-wide association studies have revealed interesting novel loci whose pathophysiological significance is incompletely understood at present. Variation in gene expression may be an important intermediate link between common genetic variants and phenotypes. In our study, combining information from genomewide association studies and global gene expression in peripheral blood monocytes, a cell type central to the atherosclerotic process, we identified interesting single nucleotide polymorphisms in the lysosomal acid lipase A gene on chromosome 10q23 in relation to CAD. Lysosomal acid lipase A gene expression was also associated with endothelial function, an intermediate phenotype of CAD. Consistent associations at the genetic, gene expression, subclinical disease, and disease levels support a causal relationship and add a pathophysiologically plausible candidate for future investigation in cardiovascular risk assessment as well as a potential therapeutic target at all stages of the disease process. The approach of combining genome-wide association studies information and global gene expression shows a successful way to further exploit genome-wide data in relation to CAD. If further confirmed, biomarkers of the lysosomal acid lipase A pathway may be candidate markers for risk prediction in primary and secondary prevention and may potentially serve as targets for interventional strategies if proven to be causal.
Conclusions:
The use of data on genetic variants and the addition of data on global monocytic gene expression led to the identification of the novel functional CAD susceptibility locus lysosomal acid lipase A, located on chromosome 10q23.31. The respective eSNPs associated with CAD strongly affect lysosomal acid lipase A gene expression level, which was related to endothelial dysfunction, a precursor of CAD. 27
Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure: The Framingham Heart Study
Summary: Left ventricular (LV) remodeling is a central process in the pathophysiology of heart failure. However, the factors that influence remodeling patterns in individuals remain unclear. Clinical determinants, such as age, sex, blood pressure, and body size, only partially explain the interindividual variability of LV geometry in the population. We investigated the role of familial factors by studying a large, 2-generational community-based sample from the Framingham Heart Study undergoing echocardiography in middle to late adulthood. We found strong evidence of concordance of LV geometry among related pairs of individuals within nuclear families (parent-child, sibling-sibling) but not among unrelated spousal pairs. The presence of a family member with abnormal LV geometry was associated with a 20% increased odds of altered LV geometric pattern in the offspring compared with the prevalence in our study population. Specifically, there was a 40% increased odds of eccentric hypertrophy or concentric remodeling and an almost 4-fold increased odds of concentric hypertrophy among family members of individuals with the corresponding abnormal LV geometric pattern. These associations remained significant after accounting for clinical factors known to influence LV geometry. Furthermore, there was an association between parental heart failure and prevalence of eccentric LV geometry in their offspring. These data demonstrate a potential contribution of familial predisposition to patterns of LV remodeling and suggest that familial factors may play a role in adverse LV remodeling and heart failure progression in the community.
Conclusions: Our investigation of a 2-generational community-based sample demonstrates familial aggregation of LV geometry, with the greatest recurrence risk for concentric LV geometry, and establishes an association between eccentric LV geometry and parental HF. 28
Association of Scavenger Receptor Class B Type I Polymorphisms With Subclinical Atherosclerosis: The Multiethnic Study of Atherosclerosis
Summary: Cardiovascular diseases constitute a major public health problem. On the basis of the findings in mice that deficiency of the scavenger receptor class B type I receptor was associated with altered lipoprotein profile and accelerated atherosclerosis, we examined the association of variation in the scavenger receptor class B type I gene with lipid phenotypes and measures of subclinical atherosclerosis in participants of the Multiethnic Study of Atherosclerosis. The results of our study demonstrate that variation within the scavenger receptor class B type I gene is associated with lipid phenotypes and subclinical atherosclerosis. One variant, rs10846744, was significantly associated with common carotid intimal thickening across the different ethnic/racial groups, with a particularly strong association in women. 
Conclusions
Postgenomic Update on a Classical Candidate Gene for Coronary Artery Disease: ESR1
Summary: After age, male sex is the most important risk factor for cardiovascular disease; however, little research has been carried out to understand the underlying causes of sex-related risk, in comparison with work on modifiable risk factors. Although the physiological differences between the sexes are evident, the genetic differences are minimal because sex is determined by the presence (in men) of a single gene, SRY, on chromosome Y. This leads to the important conclusion that male sex itself is not a cardiovascular risk factor but a proxy variable that captures a large fraction of risk via other unknown, possibly modifiable, metabolic factors that differ between men and women. Sex hormone metabolism is a prime candidate system for explaining sex differences in risk. In this highly powered study, the authors perform an extensive survey of a broad range of genetic variation in the ESR1 gene, which encodes the principal candidate for explaining sex-related differences in coronary artery disease (CAD) risk, estrogen receptor α. Despite the central role of estrogen receptor α in sex hormone signaling, its widespread expression in vascular tissues, and the importance of sex for CAD risk, the authors find no evidence for the involvement of genetic variation in ESR1 in modifying CAD risk, either in the general population or separately in men and women. Against the context of a history of inconsistent results regarding this question, this study provides a reasonably conclusive answer and may stimulate a renewed effort to explore e46 Circ Cardiovasc Genet October 2012 other elements of the sex hormone system to explain sex differences in CAD risk.
Conclusions:
We suggest that future research on the genetic basis of sex-related differences in CAD risk should initially prioritize other genes in the reproductive steroid hormone biosynthesis system. 31
The Effect of Survival Bias on Case-Control Genetic Association Studies of Highly Lethal Diseases
Summary: Genetic association studies seek to establish links between specific genetic variants and phenotypes such as quantifiable traits or disease states. These studies use the same recruitment formats and are subject to many of the same types of bias that can invalidate the results of standard epidemiological studies. Survival bias, the phenomenon by which individuals are excluded from analysis of a trait because they die as a result of the trait's expression, has been suggested as a potential explanation for the lack of case-control replication of results obtained using longitudinal cohorts. A genetic variant that increases the risk of both incidence and mortality of a disease could be found in a longitudinal cohort but could remain undetected in case-controls because individuals with that variant die before study recruitment. We modeled 3 cardiovascular diseases of high lethality: myocardial infarction, acute ischemic stroke, and intracerebral hemorrhage, using existing data from population-based studies. We simulated genetic variants that modify baseline risk for both incidence and mortality from these diseases and constructed longitudinal and case-control studies to test the observed associations between our genetic variants and disease incidence. Our results suggest that the erosion of effect size caused by survival bias is small and is calculable using formulas we provide. Furthermore, study designs that can ensure 40% recruitment of lethal cases can lessen the percentage of effect of size erosion caused by survival bias. These results should help genetic researchers compare the results of genetic studies using differing recruitment frameworks.
Conclusions:
Our simulation provides formulas to allow estimation of effect size erosion, given a variant's odds ratio of disease, odds ratio of lethality, and minor allele frequencies. These formulas will add precision to power calculation and replication efforts for casecontrol genetic studies. Our approach requires validation using prospective data. 32
Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease
Summary: To date, the chromosome 9p21 region is the best-replicated independent genetic risk factor for the development of coronary artery disease (CAD), usually as incident myocardial infarction, among whites. However, whether this genetic marker is a predictor of adverse outcomes among patients with established CAD is unclear. Given that our ability to predict which individuals will develop adverse outcomes is limited, and direct-to-consumer genetics companies are offering genotyping of this locus to patients, an understanding of how well previously noted associations apply to different patient populations is important. Accordingly, we investigated whether alleles of 9p21 single nucleotide polymorphisms previously associated with increased risk for incident CAD also were associated with increased risk for adverse cardiovascular outcomes among patients with previously documented CAD. We used data from 2 cohorts: 1 enrolled with chronic stable CAD (International Verapamil SR-Trandolapril Study) and 1 enrolled at the time of an acute coronary syndrome (Investigation of Outcomes From Acute Coronary Syndromes Study). Both cohorts were followed for ≥2 years for cardiovascular outcomes. We found that the 9p21 single nucleotide polymorphisms previously associated with higher risk for incident CAD/myocardial infarction were not associated with long-term outcomes among patients with established CAD. Several other studies have also noted no association between 9p21 and prognosis, and some suggest a protective effect associated with these single nucleotide polymorphisms among patients with established CAD. Caution, therefore, is warranted when interpreting genetic tests of the 9p21 locus because the risk associated with an allele may differ depending on the patient population.
Conclusions: Our findings suggest that previously reported chromosome 9p21 single nucleotide polymorphisms, which predict incident CAD, are not associated with higher risk for adverse outcomes in patients with established CAD. The less commonly reported linkage disequilibrium block warrants further investigation. 33
A Common Variant at Chromosome 9p21.3 Is Associated With Age of Onset of Coronary Disease but Not Subsequent Mortality
Summary: The chromosome 9p21.3 locus has been identified in multiple studies as being strongly associated with the risk of developing coronary artery disease (CAD). However, once CAD is established, the effect of this locus on the progression of disease remains largely unknown. This study investigated the association between the chromosome 9p21.3 SNP rs1333049 and clinical outcomes in 2 cohorts of patients with CAD. Although no association was identified between rs1333049 and all-cause mortality or subsequent hospital admission for a cardiovascular disease event in both patient cohorts, participants carrying the high-risk CC genotype on average developed CAD 2 to 5 years earlier than the other patient groups. This earlier age of onset of CAD in patients with the high-risk genotype, if confirmed, may have important clinical implications.
Conclusions: The chr9p21.3 polymorphism rs1333049 was associated with an earlier age of disease onset in 2 coronary disease cohorts but not with poorer clinical outcome in either cohort. 34 
